Normal-BMI MASLD is associated with increased mortality, cardiovascular events, cancer, and lower GLP-1 use
The Journal of Clinical Endocrinology & Metabolism · 28.10.2026
DOI: 10.1210/clinem/dgag439 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.10.2026. Verfasst von Isabel Casimiro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, Hawai'i, United States. Die Arbeit nennt 42 Literaturangaben. Gefördert von: NIMHD NIH HHS, Hawaii Clinical Research Network for Health Equity.
Abstract (Originalsprache)
Background
Metabolic dysfunction–associated steatotic liver disease (MASLD) can occur in individuals who are not overweight or have obesity (normal-body mass index [BMI] MASLD [nbMASLD]), yet disease burden and management remain poorly characterized. We compared long-term outcomes and incretin-based therapy use between nbMASLD and overweight/obesity-associated MASLD (obMASLD) across racial and ethnic groups.
Methods
We conducted a retrospective, observational study using the TriNetX United States Network. Adults diagnosed with MASLD or metabolic dysfunction–associated steatohepatitis from 2005 to 2025 were classified using ethnicity-informed normal-BMI thresholds: <23 kg/m2 for Asian, <27 kg/m2 for Native Hawaiian and Pacific Islander, and <25 kg/m2 for White/others. Propensity score matching balanced demographic and clinical covariates. Outcomes were assessed using Kaplan–Meier analyses and Cox proportional hazards models with obMASLD as the reference group.
Results
Among 619 171 eligible patients, 51 940 matched pairs were identified. Nb-BMI MASLD was associated with higher all-cause mortality across grouped ethnic groups, with survival of 77.49% vs 83.93% in obMASLD (hazard ratio, 1.735; confidence interval, 1.653-1.822). Ethnicity-specific risks included higher myocardial infarction risk in White and Black patients, higher stroke risk in White patients, higher end-stage renal disease risk in Black patients, and increased cancers (colorectal, pancreatic and multiple myeloma) among White patients. Incretin-based therapy use was markedly lower in nbMASLD but was associated with improved survival.
Conclusion
Patients with nbMASLD demonstrated an increased mortality and ethnicity-specific clinical complications than obMASLD despite a more favorable metabolic profile. These findings demonstrate a potential treatment gap for nbMASLD patients and the shortcomings of BMI-based strategies to risk stratify MASLD patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, Hawai'i, United States.
- Department of Medicine, The Queen's Medical Center, Honolulu, Hawaii, United States.
- Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawai'i, at Manoa, Honolulu, HI.
ORCID-Profile: Isabel Casimiro
Förderung
- NIMHD NIH HHS
- Hawaii Clinical Research Network for Health Equity
Zitieren
APA
Casimiro, I., Agawa, A., Tacata, R. H. N., Lim, E., & Kuwada, S. K. (2026). Normal-BMI MASLD is associated with increased mortality, cardiovascular events, cancer, and lower GLP-1 use. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag439
Vancouver
Casimiro I, Agawa A, Tacata RHN, Lim E, Kuwada SK. Normal-BMI MASLD is associated with increased mortality, cardiovascular events, cancer, and lower GLP-1 use. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag439
BibTeX
@article{Casimiro2026,
author = {Casimiro, Isabel and Agawa, Aoi and Tacata, Rachel Haide Naraval and Lim, Eunjung and Kuwada, Scott K},
title = {Normal-BMI MASLD is associated with increased mortality, cardiovascular events, cancer, and lower GLP-1 use},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag439}
}
EUVIMED